Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. - Wikidata - awgldk - TriplyDB

Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery.

Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery.

http://www.wikidata.org/entity/Q42607562

about

Particle-mediated delivery of cytokines for immunotherapy Immunosuppressive and anti-inflammatory properties of engineered nanomaterials Remyelination Is Correlated with Regulatory T Cell Induction Following Human Embryoid Body-Derived Neural Precursor Cell Transplantation in a Viral Model of Multiple Sclerosis Micro and nanoparticle drug delivery systems for preventing allotransplant rejection Synthetic Nanoparticles for Vaccines and Immunotherapy Modelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt-β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease.Immuno-isolation of pancreatic islet allografts using pegylated nanotherapy leads to long-term normoglycemia in full MHC mismatch recipient mice Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles.Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer.Cell-Intrinsic gp130 Signaling on CD4+ T Cells Shapes Long-Lasting Antiviral Immunity Neurological disorders and therapeutics targeted to surmount the blood-brain barrier Harnessing nanoparticles for immune modulation Biomaterial Strategies for Immunomodulation.Biotargeted nanomedicines for cancer: six tenets before you begin Engineering nanomaterials to address cell-mediated inflammation in atherosclerosis.Engineering nano- and microparticles to tune immunity Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates Polymer delivery systems for site-specific genome editing Rejection and regulation: a tight balance.Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery.Applications of nanotechnology for immunology.Strategies to direct the enrichment, expansion, and recruitment of regulatory cells for the treatment of disease.Harnessing biomaterials to engineer the lymph node microenvironment for immunity or tolerance.Selective uptake of cylindrical poly(2-oxazoline) brush-antiDEC205 antibody-OVA antigen conjugates into DEC-positive dendritic cells and subsequent T-cell activation.Targeting T cell metabolism for therapy.Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine.Immunomodulatory properties of the IL-6 cytokine family in multiple sclerosis.Paracrine co-delivery of TGF-β and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells.Regulatory T cell-based therapies for autoimmunity.Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF)An in silico analysis of nanoparticle/cell diffusive transfer: application to nano-artificial antigen-presenting cell:T-cell interaction.Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy.T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.Polymeric Biomaterials: Diverse Functions Enabled by Advances in Macromolecular Chemistry.Leukemia Inhibitory Factor-Loaded Nanoparticles with Enhanced Cytokine Metabolic Stability and Anti-Inflammatory Activity.Stem cell therapy versus T lymphocytes: friend or foe?Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer.Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy.Regulation of T-Cell Signaling by Post-Translational Modifications in Autoimmune Disease.Ex Vivo Induced Regulatory Human/Murine Mesenchymal Stem Cells as Immune Modulators.

P2860

Q26997993-4253F001-1C46-481A-BB0C-7C450F38C7BC Q27005267-0B1C7FC0-281D-40DA-B5AA-6019AB9E96E6 Q27339236-019B1BBC-20F4-4E74-A3B9-57EEB5D0D136 Q28080720-1C754EE9-CA2D-4655-BE69-9A1643CF1AFA Q28085375-8BC3131F-5910-473D-B379-F69C252E53AD Q34241152-0DCB955A-44B8-482C-99A6-06DC64D247D9 Q34506953-9FBA9284-0067-46AD-8C11-2EF67C75A896 Q34675068-B99DD96A-5E1A-4C78-B8D0-19D9DE6D5ADD Q35625854-E98BC5D2-C5B0-4EC6-A4C8-56066FBC1C4D Q35864505-57E2ECA8-59A1-4671-8BA6-CC29F13E8893 Q36119574-57056DFF-1CFD-4266-BED9-4E5449A23AC6 Q36154772-46A4A85A-2709-468A-8A14-6D97BD1D275A Q36703124-C2F17B4D-5DD0-4610-985F-93602F0049F0 Q36814280-C687B5D8-A8B0-4923-A436-F86C2846AACD Q36848196-B206FEB0-C018-4D3B-9EA7-D5E1710082EA Q37205125-2205D4D1-8CA0-4330-91D0-53F2CCD5E185 Q37238542-2859A247-0262-4D16-8A3B-7879392DEB20 Q37881210-37228659-D1BD-40DA-B8AA-D214D72071E1 Q37966922-B8628208-9F42-4204-973B-8FA1D3D896F9 Q38067265-4AF929BE-427F-44F9-8887-489C8FB0EDD6 Q38123937-F1311293-DBD6-4334-A89D-3648DD753CD6 Q38253203-E18C6435-CECB-47C1-A38B-E4D90386E1FB Q38297557-39D6D734-106E-4F50-9696-94EEB216B806 Q38305108-31F5D2AB-6372-4374-8988-B16DF57C32F6 Q38324388-8F22ABB9-3789-4F91-B6AA-3C3B65EECC74 Q38418305-BB2662B1-300E-4D17-BD5F-62D4F124C69D Q38534740-93A0D3D2-B2EE-403F-89B7-EA1716DB03B9 Q38874906-40DB5590-ED51-457C-9973-3590D878532B Q38943933-CCD15ECB-28C7-4134-AE96-B5D87F24E22D Q40617937-3850C94A-EAEC-47AF-9485-EC9A297CC374 Q41477320-12D80D32-F9F7-435B-AA49-CDB84299F37B Q42065629-806F0243-FED6-46F6-A898-CD5B3455AE14 Q47132997-58112BA2-0A23-48B6-AE0E-C7F8F5AA1A4E Q47335627-B7D7B966-1074-4E13-9150-7C67C9C78E24 Q47755745-7304B980-701F-46FC-A0EC-48BE75E6245C Q48490621-892F729B-0E29-413C-B081-7984041A246F Q49787181-25F84B70-129A-4F81-9EC2-E4CC3E87A751 Q51799863-E67EFC9D-38DB-4BBC-A2E5-12A0C48A55B1 Q52689527-B0B18353-5C4E-421F-88C3-683989E2C34F Q53554451-1B5E166E-3CC5-40F2-A946-EC0A5B1BCFEE

P2860

Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery.

http://www.wikidata.org/entity/Q42607562

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Modulation of CD4+ T lymphocyt ...... le-mediated cytokine delivery.

@en

Modulation of CD4+ T lymphocyt ...... le-mediated cytokine delivery.

@nl

type

label

Modulation of CD4+ T lymphocyt ...... le-mediated cytokine delivery.

@en

Modulation of CD4+ T lymphocyt ...... le-mediated cytokine delivery.

@nl

prefLabel

Modulation of CD4+ T lymphocyt ...... le-mediated cytokine delivery.

@en

Modulation of CD4+ T lymphocyt ...... le-mediated cytokine delivery.

@nl

P1433

Q42607562-92C39B14-0A89-4823-A9A9-1BB967EAA915

P1476

Q42607562-9D0D43D8-BAB9-45AE-98E0-789ED1DC3118

P2093

Q42607562-0B9805DF-DD7A-4DAC-A1E9-BE67F185B678

Q42607562-1AB3B3F1-34B2-4EEC-9CD2-A50EA2B770D5

Q42607562-49CAC9D6-3F54-4E23-97DB-93E9C05D4050

Q42607562-80A06431-833C-46FF-B547-E19D3923104A

Q42607562-BC91DB55-3065-42FE-BD57-97EBE12B9241

Q42607562-C3B088EC-BE3F-41A3-B93B-4948348B5AD3

P2860

Q42607562-1A762CA3-A895-452C-8710-5B50EA87BFB2

Q42607562-22CAA829-E4A8-41D9-ABBC-DF6A60D1FFE3

Q42607562-283C58CC-1CE9-493F-BDDC-74A2D08BF214

Q42607562-2F8081F6-736A-4BC5-A227-512C35944CD9

Q42607562-2FB5DA99-DF09-4624-BD01-1973689788B8

Q42607562-5C0ACFE8-6D0E-43D5-81FA-E58902BE2561

Q42607562-66C70841-7598-4C69-B53B-3283E9430156

Q42607562-6EC9D09C-A8EC-483A-8149-1228C0C8F51A

Q42607562-8072B5C2-7F29-454C-9FD3-890602F3095D

Q42607562-834C7817-BAF3-438C-A4B6-46C6395F1F2E

P304

Q42607562-324BEDD6-E691-434A-A013-209A7DFED769

P31

Q42607562-453E9135-7712-4254-AD74-AB3E979516F6

P356

Q42607562-B68C6057-99D0-4D48-8960-867306D2B1D7

P407

Q42607562-6ED48DBD-15A0-4D21-9B6C-4346AE86D072

P433

Q42607562-F731E2BC-B0DE-473E-B0D5-E54F4983C609

P478

Q42607562-7002D4FB-AF85-4A09-9B83-9ED8C30FFE60

P577

Q42607562-87570485-2AD1-4D0C-86BF-D6CC1BC130C2

P5875

Q42607562-8C54C2AE-1540-48B6-815C-980BFDEDDC12

P698

Q42607562-CA3DFDBB-C9AE-45AB-9E88-697A7EBAF011

P921

Q42607562-465A2BE9-6D8F-4F5A-81A3-97015F5F7D58

P932

Q42607562-19C0E1B3-3903-42F6-A3A8-F510CA212D3A

P356

P1433

Molecular Pharmaceutics

P1476

Modulation of CD4+ T lymphocyt ...... le-mediated cytokine delivery.

@en

P2093

Jason Park

http://www.w3.org/2001/XMLSchema#string

Roy Whiston

http://www.w3.org/2001/XMLSchema#string

Su Metcalfe

http://www.w3.org/2001/XMLSchema#string

Tarek M Fahmy

http://www.w3.org/2001/XMLSchema#string

Terry B Strom

http://www.w3.org/2001/XMLSchema#string

Wenda Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

Human T regulatory cell therapy: take a billion or so and call me in the morning

Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy

Th17 and regulatory T cells in mediating and restraining inflammation.

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6.

Evidence for functional inter-relationships between FOXP3, leukaemia inhibitory factor, and axotrophin/MARCH-7 in transplantation tolerance.

Control of regulatory T cell lineage commitment and maintenance.

Plasticity of CD4+ T cell lineage differentiation.

Biodegradable nanoparticles for drug and gene delivery to cells and tissue.

P304

143-152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/MP100203A

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47555046

http://www.w3.org/2001/XMLSchema#string

P698

20977190

http://www.w3.org/2001/XMLSchema#string

P921

P932

3040098

http://www.w3.org/2001/XMLSchema#string